Investors in Novo Nordisk (CPSE:NOVO B) have just gotten a major jolt with fresh data from the STEER real-world study, presented at the European Society of Cardiology Congress 2025. The company’s obesity drug Wegovy showed a strikingly greater reduction in risk for serious cardiovascular events compared to tirzepatide, among people living with obesity and established cardiovascular disease but no diabetes. With a 57% greater risk reduction for heart attack, stroke, and deaths from any cause...
Energinet recently announced it has awarded NKT a contract worth about €650 million to deliver 525 kV HVDC on- and offshore power cable systems connecting the Bornholm Energy Island to Zealand, a key part of Denmark’s renewables infrastructure upgrade.
This award underlines NKT’s increasing involvement in landmark European energy transition projects and advances its sustainability profile through low-carbon manufacturing and installation practices.
We'll now examine how this significant...
Sydbank announced results for the half year ended June 30, 2025, reporting net interest income of DKK 1,930 million and net income of DKK 1,207 million, both lower than the previous year, while also completing a share buyback program totaling 1,138,104 shares for DKK 490 million.
The bank also issued new profit after tax guidance for 2025, forecasting annual earnings between DKK 2,200 million and DKK 2,600 million, giving investors a fresh outlook for the year.
With these updates, we'll...
On August 26, 2025, Genmab announced that the U.S. FDA granted Breakthrough Therapy Designation to its investigational antibody-drug conjugate Rina-S for adult patients with recurrent or progressive endometrial cancer who progressed after prior platinum-based and PD-(L)1 therapies.
This regulatory milestone spotlights Rina-S as a leading late-stage asset within Genmab's expanding oncology portfolio, reflecting the growing recognition of its promise in difficult-to-treat cancers.
We'll...
ALK-Abelló A/S recently reported its second quarter and six-month 2025 earnings, highlighting sales growth to DKK 1,527 million and DKK 3,049 million respectively, with net income also rising compared to the previous year.
This improved financial performance, including higher basic and diluted earnings per share from continuing operations, signals strengthened profitability and operational momentum during the reporting periods.
With sales and earnings exceeding last year's results, we'll now...
At the recent European Society of Cardiology Congress in Madrid, Novo Nordisk presented results from the STEER real-world study showing that Wegovy® markedly reduced major cardiovascular events compared to tirzepatide among patients with obesity and established cardiovascular disease, but without diabetes.
This new evidence, based on real-world patient data, strengthens Wegovy®’s position as a potentially differentiated treatment in the growing obesity and cardiometabolic space.
We'll...
